Relmada Therapeutics, Inc. Raises $100M to Fuel Clinical Pipeline

Relmada Therapeutics, Inc. today announced it has secured $100,000,000 in investment capital from a group of investors. This significant funding round will support the continued development and advancement of the company’s clinical programs. Relmada Therapeutics is a clinical-stage biotechnology company dedicated to advancing innovative breakthrough therapies designed to bring meaningful clinical benefits to specific patient populations. The company's lead investigational program, NDV-01, is currently being evaluated in a Phase 2 study for High-Grade Non-Muscle Invasive Bladder Cancer. Additionally, Relmada is preparing to advance sepranolone, a Phase 2b-ready investigational program aimed at compulsion-related disorders, including Tourette’s Syndrome and Prader-Willi syndrome, into further clinical studies. The newly raised capital underscores the ongoing confidence in Relmada Therapeutics’ pipeline and its strategic direction. The company plans to deploy these funds to accelerate its research and development efforts, supporting the progression of its promising investigational therapies through clinical trials. This investment is crucial for expanding the company’s operational capabilities as it moves towards potentially bringing novel treatments to market. This funding positions Relmada Therapeutics for sustained growth and enables the company to intensify its focus on its mission. By strengthening its financial foundation, Relmada aims to expedite the development of its therapeutic candidates, ultimately aspiring to deliver innovative solutions for patients with high unmet medical needs. The company anticipates this investment will facilitate the critical next steps in its journey to broaden its impact on patient care.